Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00531921 |
Recruitment Status :
Completed
First Posted : September 19, 2007
Last Update Posted : June 4, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Heart Transplantation Kidney Transplantation Liver Transplantation Lung Transplantation |
Inflammation and injuries to transplanted organs during the immediate post-operative period may be linked to early organ dysfunction and higher rates of transplant rejection in the recipient. Currently, mRNA expression of proinflammatory genes in donor tissues is thought to be a risk factor for early organ transplant dysfunction, increased expression of the recipients cell-mediated immunity genes, and organ rejection. The purpose of this study is to test the association between proinflammatory mRNA expression in donor samples and subsequent development of early organ dysfunction in kidney, lung, and liver transplant recipients. This study will also test the effects of proinflammatory mediators expressed in the transplanted organ pre- and post-reperfusion on organ rejection and genes expressed in cell mediated immune responses. This will be achieved by identifying the proinflammatory immune responses and their mechanisms.
This study will consist of up to 11 study visits over a period of 2 years. The baseline visit will occur 24 hours prior to organ transplantation. Follow-up visits will occur daily for Days 1 to 3 (for lung transplant recipients only) and on Day 7, Week 6, and Months 3, 6, 9, 12, 18, and 24 post-transplant. At the baseline visit, a physical exam, medical history, demographics, vital signs measurements, blood collection, and collection of donor tissue sample will occur. For most or all other study visits, medication and adverse events tracking and blood collection will occur. Depending on the transplant type, participants will undergo the following procedures:
- Heart: Participants will undergo a heart biopsy that is part of standard clinical care following a heart transplant. An echocardiogram and an electrocardiogram will occur at most visits.
- Kidney: Renal biopsies will be performed 1 hour after reperfusion at the time of surgery. Urine collection will occur at most visits.
- Liver: Liver biopsies will be performed at the time of procurement and within 1 hour of reperfusion.
- Lung: Participants will undergo bronchoalveolar lavage that is part of standard clinical care following a lung transplant. A chest x-ray, an arterial blood gas test, a pulmonary function test, and 6-minute walking test will occur at some visits.
Study Type : | Observational |
Actual Enrollment : | 313 participants |
Observational Model: | Case-Only |
Time Perspective: | Prospective |
Official Title: | Correlation of Donor Proinflammatory mRNA Profiles With Early Outcomes of Thoracic and Abdominal Transplantation |
Study Start Date : | September 2007 |
Actual Primary Completion Date : | August 2011 |
Actual Study Completion Date : | August 2011 |

Group/Cohort |
---|
Kidney transplants
patients from 5 specific sites
|
Liver transplants
patients from 5 specific sites
|
Heart transplants
patients from 5 specific sites
|
Lung transplants
patients from 5 specific sites
|
- Association between proinflammatory mRNA expression in donor samples and subsequent development of early organ dysfunction in the immediate period following transplantation [ Time Frame: Within first 7 days after transplant ]
- Association of mRNA expression of proinflammatory mediatros in the transplanted organ in the immediate pre and post-reperfusion period with subsequent incidence of acute rejection and expression of genes involved in cell mediated immunity [ Time Frame: 12 months after transplant ]
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | up to 70 Years (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria for all participants:
- Received single lung, heart, kidney, or liver transplant
- Specimens of donor tissues have been collected
- Parent or guardian willing to provide informed consent, if applicable
Inclusion Criteria for Kidney or Liver Transplant Participants:
- 70 years old or younger
Inclusion Criteria for Heart or Lung Transplant Participants:
- Between 16 and 70 years old
Exclusion Criteria for All Participants:
- Previous solid organ transplant
- Need for combined organ transplant
- HIV or hepatitis C virus infection
- Recipient of an organ from a hepatitis C virus-infected donor
- Clinical evidence of systemic bacterial infection in the recipient at the time of transplantation
- Living donor transplant recipient of either a kidney, liver, or lung

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00531921
United States, Illinois | |
Northwestern Memorial Hospital (kidney and liver) | |
Chicago, Illinois, United States, 60611 | |
United States, New York | |
Cornell University Medical College (kidney) | |
Ithaca, New York, United States, 14850 | |
Columbia University (lung and liver) | |
New York, New York, United States, 10032 | |
United States, Pennsylvania | |
University of Pennsylvania (heart, kidney, liver, lung) | |
Philadelphia, Pennsylvania, United States, 19104 | |
United States, Wisconsin | |
University of Wisconsin (heart and lung) | |
Madison, Wisconsin, United States, 53706 |
Principal Investigator: | Abraham Shaked, MD, PhD | University of Pennsylvania Medical Center |
Publications of Results:
Other Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | National Institute of Allergy and Infectious Diseases (NIAID) |
ClinicalTrials.gov Identifier: | NCT00531921 |
Other Study ID Numbers: |
DAIT CTOT-03 |
First Posted: | September 19, 2007 Key Record Dates |
Last Update Posted: | June 4, 2013 |
Last Verified: | June 2013 |
Heart Diseases Kidney Diseases Liver Diseases Liver Failure Lung Diseases |
Transplant Transplantation, Homologous Rejection Kidney Failure |